Skip to main content
Premium Trial:

Request an Annual Quote

Signal Genetics Regains Compliance With Nasdaq Listing Requirement

NEW YORK (GenomeWeb) – Signal Genetics said today that it has received a letter from Nasdaq notifying the company that it has regained compliance with the Nasdaq Capital Market's minimum bid price requirement for continued listing.

The letter noted that as of Nov. 21 the company evidenced a closing bid price of its common stock in excess of the $1 minimum requirement for at least 10 consecutive trading days.

Earlier this month Signal and Miragen Therapeutics announced their plans to merge, to divest Signal's molecular diagnostic assets, and to form a company fully focused on Miragen's microRNA therapeutics programs.

As part of the deal, which is expected to close in the first quarter of 2017, privately held Miragen will pick up Signal's Nasdaq listing.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.